Form 4 for VRCA Verrica Pharmaceuticals Inc.
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-14 · accession 0001415889-25-008505 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-18 | 2025-03-17 | VRCA | Hayes Christopher G. | CLO | S - Sale | $0.65 | -4,315 | 176.5K | -2% | -$2,805 |
| D | 2025-03-18 | 2025-03-14 | VRCA | Hayes Christopher G. | CLO | A - Grant | $0.00 | +250.0K | 250.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-17 | S | D | 4,315 | $0.65 | 176,458 | D | — | — | (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6378 to $0.6605 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2025-03-14 | A | A | 250,000 | $0.00 | 250,000 | D | $0.89 · — to 2035-03-14 | 250,000 Common Stock | (F3) 50% of the total shares subject to the option shall vest on each of March 14, 2026 and March 14, 2027, subject to the Reporting Person's continuous service through such vesting date. |